Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26144124 | 0.88 | DRD2 (0.53) | DRD2DRD3DRD4MAPTHTR1A | |
| SCHEMBL30097048 | 0.85 | TP53 (0.41) | DRD2DRD3DRD4MAPTALDH1A1 | |
| SCHEMBL26141777 | 0.82 | MAPT (0.47) | DRD2DRD3DRD4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL30042364 | 0.81 | MAPT (0.46) | DRD2DRD3DRD4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL23706020 | 0.81 | MAPT (0.46) | DRD2DRD3DRD4MAPTALDH1A1 | |
| SCHEMBL23706101 | 0.77 | DRD2 (0.39) | DRD2DRD3DRD4MAPTALDH1A1 | |
| SCHEMBL23706103 | 0.77 | DRD2 (0.39) | DRD2DRD3DRD4MAPTALDH1A1 | |
| SCHEMBL30041995 | 0.77 | DRD2 (0.39) | DRD2DRD3DRD4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL28880155 | 0.76 | MAPT (0.47) | DRD2DRD3MAPTALDH1A1HPGD | |
| SCHEMBL27946081 | 0.70 | MAPT (0.75) | DRD2DRD3MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | DRD2 4549/4885DRD3 4589/4885DRD4 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.